Compare Innodata Inc (INOD) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Natera Inc. Common Stock — how do they compare? Innodata Inc trades at $51.99 (market cap $2.01B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 28.4× Innodata Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 20 Days and Natera Inc. Common Stock for 0 Days on average.
| INOD | NTRA | |
|---|---|---|
Market Cap | $2.01B | $57.03B |
Volume | 722,859 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $121.50 | $425.64 |
52-Week Low | $34.45 | $179.42 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $1.76B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD is trading at $58.38, down 2.55% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 42.71% gross margins and 37.74% ROE, while expanding into motion-capture AI labs and agentic reinforcement learning. Analyst consensus remains positive with 66.7% buy ratings, though valuation metrics appear elevated with a P/E of 45.26.
The outlook balances strong AI services growth against premium valuation concerns. Investment opportunity lies in continued execution on AI data engineering contracts with major tech companies, while risks include customer concentration and competitive pressures in the rapidly evolving AI infrastructure market.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
